159 related articles for article (PubMed ID: 23764770)
1. Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.
Hariharan K; Chu P; Murphy T; Clanton D; Berquist L; Molina A; Ho SN; Vega MI; Bonavida B
Int J Oncol; 2013 Aug; 43(2):670-6. PubMed ID: 23764770
[TBL] [Abstract][Full Text] [Related]
2. Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs.
Martinez-Paniagua MA; Vega MI; Huerta-Yepez S; Baritaki S; Vega GG; Hariharan K; Bonavida B
Mol Cancer Ther; 2012 Mar; 11(3):572-81. PubMed ID: 22267549
[TBL] [Abstract][Full Text] [Related]
3. The use of galiximab in non-Hodgkin lymphoma.
Vinjamaram S; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Lymphoma Myeloma; 2008 Oct; 8(5):277-82. PubMed ID: 18854281
[TBL] [Abstract][Full Text] [Related]
4. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Spurgeon SE; Coffey G; Fletcher LB; Burke R; Tyner JW; Druker BJ; Betz A; DeGuzman F; Pak Y; Baker D; Pandey A; Hollenbach SJ; Sinha U; Loriaux MM
J Pharmacol Exp Ther; 2013 Feb; 344(2):378-87. PubMed ID: 23220742
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
6. Galiximab: a review.
Bhat S; Czuczman MS
Expert Opin Biol Ther; 2010 Mar; 10(3):451-8. PubMed ID: 20092425
[TBL] [Abstract][Full Text] [Related]
7. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
Smith SM; Schöder H; Johnson JL; Jung SH; Bartlett NL; Cheson BD;
Leuk Lymphoma; 2013 Jul; 54(7):1405-10. PubMed ID: 23194022
[TBL] [Abstract][Full Text] [Related]
8. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
[TBL] [Abstract][Full Text] [Related]
9. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
Alas S; Bonavida B; Emmanouilides C
Anticancer Res; 2000; 20(5A):2961-6. PubMed ID: 11062708
[TBL] [Abstract][Full Text] [Related]
11. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Di Gaetano N; Xiao Y; Erba E; Bassan R; Rambaldi A; Golay J; Introna M
Br J Haematol; 2001 Sep; 114(4):800-9. PubMed ID: 11564066
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
13. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.
Leonard JP; Friedberg JW; Younes A; Fisher D; Gordon LI; Moore J; Czuczman M; Miller T; Stiff P; Cheson BD; Forero-Torres A; Chieffo N; McKinney B; Finucane D; Molina A
Ann Oncol; 2007 Jul; 18(7):1216-23. PubMed ID: 17470451
[TBL] [Abstract][Full Text] [Related]
15. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.
Czuczman MS; Thall A; Witzig TE; Vose JM; Younes A; Emmanouilides C; Miller TP; Moore JO; Leonard JP; Gordon LI; Sweetenham J; Alkuzweny B; Finucane DM; Leigh BR
J Clin Oncol; 2005 Jul; 23(19):4390-8. PubMed ID: 15994148
[TBL] [Abstract][Full Text] [Related]
17. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.
Al-Katib A; Arnold AA; Aboukameel A; Sosin A; Smith P; Mohamed AN; Beck FW; Mohammad RM
Mol Cancer; 2010 Sep; 9():228. PubMed ID: 20809973
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
19. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
20. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
